The Readout Loud cover image

The Readout Loud

351: It's gonna be May (in biotech)

May 1, 2025
Join Gideon Gil, Managing Editor at STAT, and Zach Tracer, Senior Editor at STAT, as they explore major shifts in the biotech landscape following the Trump administration's first 100 days. They delve into the recent resurgence of biotech mergers and acquisitions and highlight the impressive launches of new drugs. The discussion also touches on Eli Lilly's challenges regarding patient access and the competitive dynamics with Novo Nordisk. Humorously, they juxtapose industry insights with pop culture, featuring a nod to a Justin Timberlake meme.
35:19

Podcast summary created with Snipd AI

Quick takeaways

  • The Trump administration's first 100 days caused significant disruptions in federal health agencies, resulting in fewer research grants and halted projects.
  • A resurgence in biotech mergers and acquisitions signals market recovery, with notable deals indicating increased confidence in the industry's future.

Deep dives

The Impact of the Trump Administration on Health Agencies

The first 100 days of the Trump administration significantly disrupted federal health agencies and the biotech industry. Key changes included a substantial reduction in staff at the FDA, NIH, and CDC, leading to halted research grants and canceled advisory committee meetings. Reports indicate that the NIH approved $2.3 billion fewer new grants during this period compared to previous administrations, impacting funding for vital research. These shifts have created an atmosphere of uncertainty, compelling many universities to freeze hiring and admissions, further destabilizing the scientific community.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner
Get the app